Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Gensight Biologics SA Stock

Price
Target price
€0.36

€0.36

-2.420%
-0.009
-2.420%
-
 
07.05.24 / Stuttgart Stock Exchange WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Gensight Biologics SA in the next few years
Wizard

Financial data and news for Gensight

sharewise wants to provide you with the best news and tools for Gensight, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration: https://mms.businesswire.com/media/20240319984906/en/2072888/5/Graph_1_ENG.jpg
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319984906/en/



Graph 1: Evolution of Best-Corrected Visual Acuity


BusinessWire_EN 
0 20.03.24
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024: https://mms.businesswire.com/media/20240311531952/en/2062971/5/Figure_1_ENG.jpg
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311531952/en/



Figure 1. Visual Recovery (CRR from Nadir) Among


BusinessWire_EN 
0 12.03.24
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024: https://mms.businesswire.com/media/20240305810568/en/2056132/5/Figure_1_-_BCVA_EAP_-_ENG.jpg
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305810568/en/



(Graphic: Business Wire)




GenSight Biologics

BusinessWire_EN 
0 06.03.24
GenSight Biologics: Annual General Meeting on May 29, 2024: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics: Annual General Meeting on May 29, 2024


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

BusinessWire_EN 
0 07.05.24
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

BusinessWire_EN 
0 18.04.24
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update


Regulatory News:



GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing

BusinessWire_EN 
0 04.04.24
GenSight Biologics Announces its 2024 Financial Calendar: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces its 2024 Financial Calendar


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

BusinessWire_EN 
0 04.04.24
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

BusinessWire_EN 
0 22.03.24
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal

BusinessWire_EN 
0 04.03.24